Aligos Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Aligos Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Aligos Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$26.4M, a 38% decline year-over-year.
  • Aligos Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$93.5M, a 10.4% decline year-over-year.
  • Aligos Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$88.1M, a 9.69% increase from 2022.
  • Aligos Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$97.6M, a 24% increase from 2021.
  • Aligos Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$128M, a 31.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$88.1M +$9.45M +9.69% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-12
2022 -$97.6M +$30.7M +24% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-12
2021 -$128M -$30.5M -31.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 -$97.8M -$43.8M -81% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 -$54M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.